Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 5, 2014, Pages 730-734

  Yeh, Albert C ^a   Brunner, Andrew M ^a   Spitzer, Thomas R ^a   Chen, Yi Bin ^a   Coughlin, Erin ^a   McAfee, Steven ^a   Ballen, Karen ^a   Attar, Eyal ^a   Caron, Martin ^a   Preffer, Frederic I ^a   Yeap, Beow Y ^a   Dey, Bimalangshu R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Allogeneic transplant; GVHD; Urate oxidase

Indexed keywords

ALLOPURINOL; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; RASBURICASE; TACROLIMUS; THYMOCYTE ANTIBODY; URIC ACID; MYELOABLATIVE AGENT; RECOMBINANT PROTEIN; URATE OXIDASE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RADIOTHERAPY; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; FEASIBILITY STUDY; FEMALE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMATOLOGIC MALIGNANCY; HEMOLYTIC ANEMIA; HUMAN; INFECTION PREVENTION; INTRAVASCULAR HEMOLYSIS; MALE; MUCOSA INFLAMMATION; MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NAUSEA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PHASE 1 CLINICAL TRIAL; RADIATION DOSE DISTRIBUTION; TONGUE DISEASE; TREATMENT DURATION; URIC ACID BLOOD LEVEL; VOMITING; WHOLE BODY RADIATION; ACUTE DISEASE; ALLOTRANSPLANTATION; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; MIDDLE AGED; MORTALITY; PATHOLOGY; REMISSION; SURVIVAL; T LYMPHOCYTE;

ACUTE DISEASE; ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RECOMBINANT PROTEINS; REMISSION INDUCTION; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; URATE OXIDASE; URIC ACID;

EID: 84897959355     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.02.003     Document Type: Article

References (14)

1. Blazar B.R., Murphy W.J., Abedi M. Advances in graft-versus-host disease biology and therapy. Nature reviews. Immunology 2012, 12:443-458.
2. Shlomchik W.D. Graft-versus-host disease. Nature reviews. Immunology 2007, 7:340-352.
3. Weisdorf D., Hakke R., Blazar B., et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991, 51:1197-1203.
4. Jagasia M., Arora M., Flowers M.E., et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012, 119:296-307.
5. Socie G., Blazar B.R. Acute graft-versus-host disease: from the bench to the bedside. Blood 2009, 114:4327-4336.
6. Shi Y., Evans J.E., Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.
7. Hu D.E., Moore A.M., Thomsen L.L., Brindle K.M. Uric acid promotes tumor immune rejection. Cancer Res 2004, 64:5059-5062.
8. Shi Y., Galusha S.A., Rock K.L. Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model. JImmunol 2006, 176:3905-3908.
9. Pui C.H. Rasburicase: a potent uricolytic agent. Exp Opin Pharmacother 2002, 3:433-442.
10. Goldman S.C., Holcenberg J.S., Finklestein J.Z., et al. Arandomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001, 97:2998-3003.
11. Pui C.H., Mahmoud H.H., Wiley J.M., et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. JClin Oncol 2001, 19:697-704.
12. Thomas E.D., Storb R., Clift R.A., et al. Bone-marrow transplantation (second of two parts). NEngl J Med 1975, 292:895-902.
13. Gray R.J. Aclass of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
14. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.